Taysha Gene Therapies (TSHA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.11
- Surprise
- —
- Score today
- 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates TSHA Sell at 5.5/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Pipeline: TSHA-102
- Concentration risk — Counterparty: UT Southwestern
- Quality below floor (3.4 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $5.47
- Price target
- $11.60
- Stop
- $5.27
- Upside to target
- +112.1%
- Reward-to-risk
- 10.9:1
Risk check: RSI 28 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
TSHA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.81B
- P/E (fwd)
- -12.0
- 52-week range
- $2.71–$7.30
- Off 52-week high
- 25.1%
- RSI (14)
- 28
- Volume vs avg
- 0.12×
- Score today
- 5.5/10